Today we shared landmark top-line results from our Phase 3 PEAK trial in #GIST achieving 16.5 months median progression free survival with the bezuclastinb plus sunitinib combination compared to 9.2 months with sunitinib monotherapy. Our webcast will begin this morning at 8am ET. We invite you to join here: https://bit.ly/3Xlop6c and read the release: https://bit.ly/3JL9LlE. We are deeply grateful to the patients, families, and researchers whose participation in PEAK helped make this possible.
Incredible teamwork and trust-based collaborations established across Cogent and externally with thought leaders, healthcare providers, and advocates alike. Thank you to all who contributed to the Peak trial especially patients and their families.
This is exciting news for the #GIST patient community! It shows what’s possible when companies stay committed to advancing promising therapies.
Looking forward to hearing more about this promising work at CTOS this week!
Wonderful to see this data - congrats to the Cogent Biosciences PEAK trial team! 🎉
Congratulations to the team at Cogent Biosciences!!!
This is such amazing news for the GIST patients 🙌🏽
Congratulations!!
Great news!
Congrats !
Remarkable achievement — congratulations to the Cogent Biosciences team and all clinical partners involved. Advancing progression-free survival this significantly represents a major step forward for patients living with GIST and a testament to the power of targeted, science-driven collaboration.